[go: up one dir, main page]

WO2008106606A3 - Carotenoid analogs and derivatives in the treatment of prostate cancer - Google Patents

Carotenoid analogs and derivatives in the treatment of prostate cancer Download PDF

Info

Publication number
WO2008106606A3
WO2008106606A3 PCT/US2008/055334 US2008055334W WO2008106606A3 WO 2008106606 A3 WO2008106606 A3 WO 2008106606A3 US 2008055334 W US2008055334 W US 2008055334W WO 2008106606 A3 WO2008106606 A3 WO 2008106606A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
treatment
prostate cancer
carotenoid analogs
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055334
Other languages
French (fr)
Other versions
WO2008106606A2 (en
Inventor
Timothy J King
Samuel F Lockwood
Andrew David Hieber
Nicholas J Shubin
Henry J Jackson
Geoffry T Nadolski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardax Pharmaceuticals Inc
Original Assignee
Cardax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardax Pharmaceuticals Inc filed Critical Cardax Pharmaceuticals Inc
Publication of WO2008106606A2 publication Critical patent/WO2008106606A2/en
Publication of WO2008106606A3 publication Critical patent/WO2008106606A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of prostate cancer, BPH or prostatitis. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of prostate cancer. Yet further embodiments provide for methods of treating prostate cancer that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting or reducing one or more components of NF-κB signaling in the subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional compositions or medicaments suitable for the treatment of prostate cancer.
PCT/US2008/055334 2007-02-28 2008-02-28 Carotenoid analogs and derivatives in the treatment of prostate cancer Ceased WO2008106606A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90407007P 2007-02-28 2007-02-28
US60/904,070 2007-02-28

Publications (2)

Publication Number Publication Date
WO2008106606A2 WO2008106606A2 (en) 2008-09-04
WO2008106606A3 true WO2008106606A3 (en) 2009-07-02

Family

ID=39494322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055334 Ceased WO2008106606A2 (en) 2007-02-28 2008-02-28 Carotenoid analogs and derivatives in the treatment of prostate cancer

Country Status (1)

Country Link
WO (1) WO2008106606A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015262405B2 (en) 2014-05-20 2019-01-03 Asta Pharmaceuticals Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
CN118084755B (en) * 2024-04-22 2024-08-02 潍坊富邦药业有限公司 Astaxanthin derivative with high water solubility and preparation method thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277417B1 (en) * 2000-04-07 2001-08-21 Triarco Industries, Inc. Method of inhibiting 5α-reductase with astaxanthin
WO2001072296A1 (en) * 2000-03-27 2001-10-04 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
FR2820321A1 (en) * 2001-02-06 2002-08-09 Jean Pierre Oury COMPOSITION WITH PROTECTIVE EFFECT IN PROSTATIC TUMORS
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
WO2006099015A2 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
WO2006119125A2 (en) * 2005-04-29 2006-11-09 Cardax Pharmaceuticals, Inc. Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
WO2006119168A2 (en) * 2005-05-02 2006-11-09 Cardax Pharmaceuticals, Inc. Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
WO2007147163A2 (en) * 2006-06-16 2007-12-21 Cardax Pharmaceuticals, Inc. Compositions comprising carotenoid analogs or derivatives and methods for synthesis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072296A1 (en) * 2000-03-27 2001-10-04 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US6277417B1 (en) * 2000-04-07 2001-08-21 Triarco Industries, Inc. Method of inhibiting 5α-reductase with astaxanthin
FR2820321A1 (en) * 2001-02-06 2002-08-09 Jean Pierre Oury COMPOSITION WITH PROTECTIVE EFFECT IN PROSTATIC TUMORS
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
WO2006099015A2 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
WO2006119125A2 (en) * 2005-04-29 2006-11-09 Cardax Pharmaceuticals, Inc. Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
WO2006119168A2 (en) * 2005-05-02 2006-11-09 Cardax Pharmaceuticals, Inc. Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
WO2007147163A2 (en) * 2006-06-16 2007-12-21 Cardax Pharmaceuticals, Inc. Compositions comprising carotenoid analogs or derivatives and methods for synthesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GI-YOUNG K ET AL: "Lycopene Suppresses the Lipopolysaccharide-Induced Phenotypic and Functional Maturation of Murine Dendritic Cells Through Inhibition of Mitogen-Activated Protein Kinases and Nuclear Factor-kappaB", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 113, 1 January 2004 (2004-01-01), pages 203 - 211, XP003014157, ISSN: 0019-2805 *
HUANG ET AL: "Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 18, no. 7, 8 June 2007 (2007-06-08), pages 449 - 456, XP022109101, ISSN: 0955-2863 *

Also Published As

Publication number Publication date
WO2008106606A2 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
EP4140487A8 (en) Combination therapy for treating cancer
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MX387885B (en) Ezh2 inhibitors for treating lymphoma
SG10201902664RA (en) Combination therapy for treating cancer
WO2016025635A3 (en) Combination therapy for treating cancer
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
UA100979C2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
WO2016043874A3 (en) Combination therapy for treating cancer
WO2007112316A3 (en) Mycobacterial immunotherapy for cancer treatment
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2010151074A3 (en) Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
WO2008089070A3 (en) Combination therapy for the treatment of cancer
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2008106606A3 (en) Carotenoid analogs and derivatives in the treatment of prostate cancer
WO2011094260A3 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730994

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08730994

Country of ref document: EP

Kind code of ref document: A2